CFDB - Cystic Fibrosis DataBase

All subcategories » trial from other registries

Tolerability and Safety of Inhaled Colistimethate Sodium (CMS) Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection (COPILOT) - Not yet recruiting

ongoing trials  trial from other registries

Details
  • 2024

A randomised, double-blind, placebo controlled, two-part study to evaluate the efficacy, safety, tolerability and pharmacokinetics of a repeat dose of inhaled ETD001 in people with cystic fibrosis - Ongoing

ongoing trials  trial from other registries

Details
  • 2024

A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

ongoing trials  trial from other registries

Details
  • 2023

Evaluation of the effects of curcumin-piperine in reducing Pseudomonas infection and improving clinical outcome in patients with cystic fibrosis - Pending

ongoing trials  trial from other registries

Details
  • 2023

The randomized, double blind study phase III.b of the Comprehensive assessment of the musculoskeletal health in children with cystic fibrosis – on the search for means of improvement

ongoing trials  trial from other registries

Details
  • 2022

Evaluation the effects of camel milk in spirometry parameters in over 6 year’s children with Cystic Fibrosis lung disease - Recruiting

ongoing trials  trial from other registries

Details
  • 2022

A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes

ongoing trials  trial from other registries

Details
  • 2021

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

ongoing trials  trial from other registries

Details
  • 2021

A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation

ongoing trials  trial from other registries

Details
  • 2021

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation

ongoing trials  trial from other registries

Details
  • 2021